Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2016 at the end of the period of market exclusivity.
On 23 December 2005, orphan designation (EU/3/05/338) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for dasatinib for the treatment of acute lymphoblastic leukaemia.
Dasatinib has been authorised in the EU as Sprycel since 20 November 2006.
|Disease / condition||
Treatment of acute lymphoblastic leukaemia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;